Speaking to CNBC-TV18, Biocon Biologics CEO and MD Shreehas Tambe called the tie-up “a very significant development—not just for Biocon, but also in terms of how insulins will be made available to patients in the United States.” He highlighted that the partnership reflects the company’s robust commercial platform, which can deliver medicines through multiple channels, from hospital networks to direct consumer distribution.
Under the deal, Biocon Biologics will manufacture and supply Insulin Glargine and other medicines to Civica. The insulin will be sold under Civica’s branding throughout the US, except for California, where it will be marketed under the CalRx brand. Civica will also manage all sales, promotion, and distribution in the US.
Tambe also outlined the scale of the opportunity, saying the insulin business in California alone could represent a potential $150-200 million market. “This is a very meaningful extension of what we already do. We have a substantial business, and this partnership allows us to reach more patients who need insulin,” he added.
He further emphasised the role of Indian generics and biosimilars in making healthcare more affordable in the US. “We are clearly part of the solution. What we’ve done with the California government is a great example of delivering affordable products directly to patients,” Tambe said, pointing to greater clarity following the closure of the Section 232 tariff investigation.
The Civica partnership allows Biocon Biologics to distribute high-quality insulin more efficiently while advancing its commitment to health equity. It also underscores the company’s long-term strategy of combining manufacturing excellence with flexible commercial channels to meet growing demand in international markets.
Watch accompanying video for entire conversation.
First Published: Oct 20, 2025 3:22 PM IST